Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.55B | 2.54B | 2.57B | 2.58B | 2.56B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.55B | 2.54B | 2.57B | 2.58B | 2.56B |
| Cost of Revenue | 1.20B | 1.18B | 1.19B | 1.18B | 1.18B |
| Gross Profit | 1.35B | 1.36B | 1.38B | 1.40B | 1.38B |
| SG&A Expenses | 803.20M | 793.90M | 810.90M | 814.06M | 814.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.30B | 2.26B | 2.29B | 2.27B | 2.22B |
| Operating Income | 259.00M | 279.90M | 274.70M | 311.69M | 338.27M |
| Income Before Tax | 450.10M | -2.75B | -2.34B | -1.01B | -1.73B |
| Income Tax Expenses | 130.93M | -586.07M | -498.27M | -226.49M | -404.09M |
| Earnings from Continuing Operations | 319.17 | -2.16K | -1.84K | -778.70 | -1.33K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 319.17M | -2.16B | -1.84B | -778.70M | -1.33B |
| EBIT | 259.00M | 279.90M | 274.70M | 311.69M | 338.27M |
| EBITDA | 415.80M | 432.50M | 426.30M | 461.29M | 486.27M |
| EPS Basic | 11.77 | -76.17 | -65.00 | -27.28 | -47.00 |
| Normalized Basic EPS | 6.64 | 7.15 | 6.93 | 7.75 | 8.42 |
| EPS Diluted | 11.73 | -76.20 | -65.04 | -27.34 | -47.04 |
| Normalized Diluted EPS | 6.63 | 7.15 | 6.93 | 7.74 | 8.41 |
| Average Basic Shares Outstanding | 111.11M | 112.28M | 112.86M | 113.65M | 114.81M |
| Average Diluted Shares Outstanding | 111.17M | 112.33M | 112.91M | 113.73M | 114.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |